Timothée Olivier/X
Dec 5, 2024, 15:21
Timothée Olivier: NATALEE trial – 3 years of adjuvant ribociclib in early breast cancer
Timothée Olivier, Medical oncologist at the Oncology Division of Geneva University, shared on X:
“NATALEE trial: 3 years of adjuvant ribociclib in early breast cancer:
iDFS benefit
OS benefit
Concerns: Informative censoring? + others!
-> it got an “A”?
Don’t stop at scores – dig deeper into the data to better inform shared decision-making.”
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Authors: Alyson Haslam, Sruthi Ranganathan, Vinay Prasad, Timothée Olivier
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 5, 2024, 15:23
Dec 5, 2024, 15:18
Dec 5, 2024, 15:16
Dec 5, 2024, 15:02
Dec 5, 2024, 14:47
Dec 5, 2024, 14:42
Dec 5, 2024, 14:39